Philadelphia positive acute lymphoblastic leukaemia of childhood

Louise K. Jones, Vaskar Saha

    Research output: Contribution to journalArticlepeer-review

    Abstract

    On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long-term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo-SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy. © 2005 Blackwell Publishing Ltd.
    Original languageEnglish
    Pages (from-to)489-500
    Number of pages11
    JournalBritish Journal of Haematology
    Volume130
    Issue number4
    DOIs
    Publication statusPublished - Aug 2005

    Keywords

    • Childhood
    • Philadelphia positive acute lymphoblastic leukaemia

    Fingerprint

    Dive into the research topics of 'Philadelphia positive acute lymphoblastic leukaemia of childhood'. Together they form a unique fingerprint.

    Cite this